"Upper respiratory infections are the most common acute illnesses in the world," said Ian Paul, M.D., M.Sc., associate professor of pediatrics and public health sciences.
"Symptoms caused by these infections are disruptive for children, and often disturb sleep for both ill children and their parents, with an impact on subsequent daytime activities. Safe and effective, evidence-based treatments are desperately needed by parents and healthcare providers for children."
Recent studies by Paul and colleagues at the Penn State College of Medicine looked at the efficacy of oral over-the-counter treatments such as dextromethorphan and diphenhydramine for upper respiratory infection symptoms. They found the preparations no more effective than a placebo. Vapor rubs, containing menthol, camphor and eucalyptus oils, have been used for over a century without published evidence to support their use.
"The American Academy of Pediatrics does not support the use of over-the-counter oral cough and cold medications for children due to a lack of evidence of efficacy and the potential for side effects," Paul said. "The question of whether clinicians can recommend a vapor rub topical treatment to treat cold symptoms required evaluation."
Paul and his research team recruited 138 children ages 2 to 11 for the study. Parents assessed their child's symptoms the night before enrollment in the study. Each child was then randomly assigned to one of three treatment groups: Vicks® VapoRub®, petroleum jelly placebo, and no treatment. Parents of children receiving the vapor rub or petroleum jelly massaged the treatment into their child's neck and chest 30 minutes before bedtime.
The randomized study was partially double-blinded. Medical staff did not know what treatment each participating family received when distributing their sealed specimen cup-containing envelope. Parents of children who received the vapor rub or petroleum jelly were blinded to their treatment group. To accomplish this, given the characteristic scent of vapor rubs, parents received their own specimen cup of vapor rub that they were instructed to apply between their own upper lip and nose before opening their child's treatment in order to ensure they could not detect the smell of their child's treatment. Parents of children in the no treatment group received an empty specimen cup.
Parents then completed a second survey the following morning assessing their child's cough, sleep, congestion and runny nose.
In comparisons across the three treatment groups, parents reported that the vapor rub provided significantly greater relief as measured by cough frequency, cough severity, congestion and the child's ability to sleep. Parents also rated their own sleep as most improved in the vapor rub group when compared across the three study groups. Paired comparisons between the vapor rub group and the no treatment group demonstrated the superiority of the vapor rub for all study outcomes except runny nose. Paired comparison of the vapor rub group to the petroleum jelly group showed vapor rub improved child's sleep, parent's sleep and the combined symptom score. The petroleum jelly placebo was not significantly better than no-treatment for any study outcome.
The most common side effect cited with the use of the vapor rub was a burning sensation of the skin, reported by 28 percent of participants receiving that treatment. No side effects were reported with use of petroleum jelly.
The results of this study suggest that an old, commonly used remedy is effective at providing symptomatic relief from night-time cold symptoms with the added benefit of improving sleep for children with colds and their parents," Paul said. "Vapor rubs have been used for generations, but this study demonstrates that this therapy is indeed effective." The research results appear in the December issue of "Pediatrics."
An unrestricted research grant from Procter and Gamble funded this study. An unrestricted grant enables the research team to design and conduct the study and analysis independently from the study sponsor, ensuring that the research can be published by the investigators regardless of whether the results are favorable to the sponsor. This study was registered at www.clinicaltrials.gov prior to its initiation (identifier NCT00743990).
Other members of the research team are Jessica Beiler, M.P.H., Edelveis R. Clapp, D.O., Julie Vallati, L.P.N., and Cheston M. Berlin Jr., M.D., all of the Department of Pediatrics; and Tonya S. King, Ph.D., Department of Public Health Sciences.
Matt Solovey | EurekAlert!
Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn
On track to heal leukaemia
18.01.2017 | Universitätsspital Bern
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
19.01.2017 | Earth Sciences
19.01.2017 | Life Sciences
19.01.2017 | Physics and Astronomy